Banco Sabadell Upgrades GRIFOLS S A/S (NASDAQ:GRFS) to Buy

Share on StockTwits

GRIFOLS S A/S (NASDAQ:GRFS) was upgraded by investment analysts at Banco Sabadell from a “sell” rating to a “buy” rating in a note issued to investors on Monday, The Fly reports.

GRFS has been the subject of several other research reports. Berenberg Bank raised GRIFOLS S A/S to a “buy” rating in a report on Wednesday, October 30th. BidaskClub raised shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Wednesday, December 4th. ValuEngine raised shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Zacks Investment Research cut shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Santander raised shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating in a report on Monday, October 28th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.75.

NASDAQ:GRFS opened at $22.97 on Monday. GRIFOLS S A/S has a 52-week low of $17.42 and a 52-week high of $23.60. The stock has a fifty day moving average of $21.81 and a 200 day moving average of $20.91. The company has a debt-to-equity ratio of 1.30, a quick ratio of 0.96 and a current ratio of 2.62. The firm has a market capitalization of $15.79 billion, a price-to-earnings ratio of 19.63, a P/E/G ratio of 1.42 and a beta of 1.06.

GRIFOLS S A/S (NASDAQ:GRFS) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.03). GRIFOLS S A/S had a return on equity of 13.58% and a net margin of 11.12%. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.39 billion. Equities analysts forecast that GRIFOLS S A/S will post 1.16 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of GRFS. Cardinal Capital Management lifted its holdings in shares of GRIFOLS S A/S by 1.1% in the 3rd quarter. Cardinal Capital Management now owns 53,914 shares of the biotechnology company’s stock worth $1,080,000 after acquiring an additional 602 shares during the last quarter. Atria Investments LLC lifted its stake in GRIFOLS S A/S by 3.6% in the second quarter. Atria Investments LLC now owns 21,033 shares of the biotechnology company’s stock worth $460,000 after purchasing an additional 734 shares during the last quarter. BB&T Corp lifted its stake in GRIFOLS S A/S by 2.5% in the third quarter. BB&T Corp now owns 35,219 shares of the biotechnology company’s stock worth $706,000 after purchasing an additional 857 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in GRIFOLS S A/S by 24.2% in the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,818 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,522 shares during the last quarter. Finally, Todd Asset Management LLC boosted its position in GRIFOLS S A/S by 0.3% during the second quarter. Todd Asset Management LLC now owns 881,908 shares of the biotechnology company’s stock valued at $18,608,000 after buying an additional 2,238 shares during the period. 18.18% of the stock is owned by institutional investors and hedge funds.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Further Reading: What is the float in trading stocks?

The Fly

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.